Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pharmacotherapeutic considerations in women with multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Treatment of adult short bowel syndrome patients with teduglutide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Therapeutic management of type 1 diabetes before and during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  5. Treating tension-type headache -- an expert opinion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irinotecan provides impressive response rates (RR), it is still uncertain if this treatment translates into improved clinical benefit in GBM patients. AREAS COVERED: This review discusses the clinical efficacy, safety and difficulties regarding response evaluation when treating with BVZ and CPT-11 in recurrent GBM. Particular attention is placed on the literature and a discussion on whether treatment with BVZ and CPT-11 improves clinical outcome. Antiangiogenic treatment has led to difficulties when evaluating objective response by the conventional MacDonald criteria. In the present paper the authors discuss selected key aspects of this treatment modality. A literature search was performed using PubMed in February 2011. EXPERT OPINION: BVZ + irinotecan leads to high RR and to an increased 6-month progression-free survival. However, no improvement in median overall survival has been observed compared with conventional chemotherapy. Nevertheless, the GBM patients who respond to treatment with BVZ and irinotecan have survived significantly longer than non-responders, indicating that it could be beneficial for a selection of patients to receive this treatment.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind12
Udgave nummer5
Sider (fra-til)825-33
Antal sider9
ISSN1465-6566
DOI
StatusUdgivet - 1 apr. 2011

ID: 32428129